201 related articles for article (PubMed ID: 29869732)
1. Sensitivity and specificity of cardiac metaiodobenzylguanidine scintigraphy in the early diagnosis of Parkinson's disease.
Brandl SJ; Braune S
Clin Auton Res; 2019 Dec; 29(6):567-574. PubMed ID: 29869732
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity and specificity of cardiac
Kawazoe M; Arima H; Maeda T; Tsuji M; Mishima T; Fujioka S; Tsugawa J; Tsuboi Y
J Neurol Sci; 2019 Dec; 407():116409. PubMed ID: 31706063
[TBL] [Abstract][Full Text] [Related]
3.
Yang T; Wang L; Li Y; Cheng M; Jiao J; Wang Q; Guo H
J Neurol Sci; 2017 Feb; 373():48-51. PubMed ID: 28131225
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of rCBF analysis in diagnosing Parkinson's disease: supplemental role with MIBG myocardial scintigraphy.
Nagamachi S; Wakamatsu H; Kiyohara S; Fujita S; Futami S; Tamura S; Nakazato M; Yamashita S; Arita H; Nishii R; Kawai K
Ann Nucl Med; 2008 Aug; 22(7):557-64. PubMed ID: 18756357
[TBL] [Abstract][Full Text] [Related]
5. 123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis.
Orimo S; Suzuki M; Inaba A; Mizusawa H
Parkinsonism Relat Disord; 2012 Jun; 18(5):494-500. PubMed ID: 22321865
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson's Disease and Atypical Parkinsonian Syndromes.
Fujita H; Suzuki K; Numao A; Watanabe Y; Uchiyama T; Miyamoto T; Miyamoto M; Hirata K
PLoS One; 2016; 11(11):e0165869. PubMed ID: 27812167
[TBL] [Abstract][Full Text] [Related]
7. (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease.
Orimo S; Ozawa E; Nakade S; Sugimoto T; Mizusawa H
J Neurol Neurosurg Psychiatry; 1999 Aug; 67(2):189-94. PubMed ID: 10406987
[TBL] [Abstract][Full Text] [Related]
8. Validation of cardiac (123)I-MIBG scintigraphy in patients with Parkinson's disease who were diagnosed with dopamine PET.
Ishibashi K; Saito Y; Murayama S; Kanemaru K; Oda K; Ishiwata K; Mizusawa H; Ishii K
Eur J Nucl Med Mol Imaging; 2010 Jan; 37(1):3-11. PubMed ID: 19626324
[TBL] [Abstract][Full Text] [Related]
9. MIBG myocardial scintigraphy in progressive supranuclear palsy.
Kamada T; Miura S; Kida H; Irie KI; Yamanishi Y; Hoshino T; Taniwaki T
J Neurol Sci; 2019 Jan; 396():3-7. PubMed ID: 30391822
[TBL] [Abstract][Full Text] [Related]
10. Initial Versus Follow-up Sequential Myocardial 123I-MIBG Scintigraphy to Discriminate Parkinson Disease From Atypical Parkinsonian Syndromes.
Ryu DW; Kim JS; Lee JE; Oh YS; Yoo SW; Yoo IR; Lee KS
Clin Nucl Med; 2019 Apr; 44(4):282-288. PubMed ID: 30589669
[TBL] [Abstract][Full Text] [Related]
11. Sequential imaging analysis using MIBG scintigraphy revealed progressive degeneration of cardiac sympathetic nerve in Parkinson's disease.
Watanabe M; Takeda T; Nakamagoe K; Tamaoka A
Eur J Neurol; 2011 Jul; 18(7):1010-3. PubMed ID: 21658161
[TBL] [Abstract][Full Text] [Related]
12. Is 123I-MIBG Scintigraphy Beneficial or Excessive for the Diagnosis of Parkinson's Disease in the Early Phase?
Ikeda T; Ikenoshita S; Sakamoto F; Shiraishi S; Nakahara K; Masuda T; Yamashita S
Neurodegener Dis; 2019; 19(2):88-95. PubMed ID: 31715596
[TBL] [Abstract][Full Text] [Related]
13. Optimal Protocol and Clinical Usefulness of
Chun IK
Nucl Med Mol Imaging; 2023 Jun; 57(3):145-154. PubMed ID: 37187951
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic performance of iodine-123-metaiodobenzylguanidine scintigraphy in differential diagnosis between Parkinson's disease and multiple-system atrophy: a systematic review and a meta-analysis.
Treglia G; Stefanelli A; Cason E; Cocciolillo F; Di Giuda D; Giordano A
Clin Neurol Neurosurg; 2011 Dec; 113(10):823-9. PubMed ID: 21962800
[TBL] [Abstract][Full Text] [Related]
15. [[(123)I]-Ioflupane SPECT in combination with MIBG myocardial scintigraphy in Parkinson's disease: a case series study].
Yamada A; Murakami T; Kang Y; Iikuni Y; Morimatsu A; Shirata A; Ito H; Ugawa Y; Yamane K
Rinsho Shinkeigaku; 2016 Jun; 56(6):400-6. PubMed ID: 27212677
[TBL] [Abstract][Full Text] [Related]
16. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease.
Nagayama H; Hamamoto M; Ueda M; Nagashima J; Katayama Y
J Neurol Neurosurg Psychiatry; 2005 Feb; 76(2):249-51. PubMed ID: 15654042
[TBL] [Abstract][Full Text] [Related]
17. PR Prolongation and Cardiac 123I-MIBG Uptake Reduction in Parkinson's Disease.
Mochizuki H; Ebihara Y; Ugawa Y; Ishii N; Taniguchi A; Nagamachi S; Shiomi K; Nakazato M
Eur Neurol; 2015; 74(1-2):107-11. PubMed ID: 26303385
[TBL] [Abstract][Full Text] [Related]
18. Myocardial MIBG scintigraphy may predict the course of motor symptoms in Parkinson's disease.
Dorschner J; Farmakis G; Behnke S; Hellwig D; Schneider S; Fassbender K; Kirsch CM; Dillmann U; Spiegel J
Parkinsonism Relat Disord; 2011 Jun; 17(5):372-5. PubMed ID: 21421334
[TBL] [Abstract][Full Text] [Related]
19. Is There Any Clinical Value of Adding 123I-Metaiodobenzylguanidine Myocardial Scintigraphy to 123I-Ioflupane (DaTscan) in the Differential Diagnosis of Parkinsonism?
Stathaki M; Koukouraki S; Simos P; Boura I; Papadaki E; Bourogianni O; Tsaroucha A; Kapsoritakis N; Mitsias P; Spanaki C
Clin Nucl Med; 2020 Aug; 45(8):588-593. PubMed ID: 32404715
[TBL] [Abstract][Full Text] [Related]
20. Levodopa challenge test and (123) I-metaiodobenzylguanidine scintigraphy for diagnosing Parkinson's disease.
Asayama S; Wate R; Kaneko S; Asayama T; Oki M; Tsuge A; Nagashima M; Morita J; Nakamura S; Nakamura M; Nishii M; Fujita K; Saito A; Nakano S; Ito H; Kusaka H
Acta Neurol Scand; 2013 Sep; 128(3):160-5. PubMed ID: 23410225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
